

Gene Editing Therapeutics Market

Market Research Report | 2024-08-30 | 111 pages | BCC Research

AVAILABLE LICENSES:

- Single User License \$5500.00
- 2-5 Users License \$6600.00
- Site License \$7920.00
- Enterprise License \$9504.00

Report description:

Description

Report Scope:

This report highlights the current and future market potential of gene editing therapeutics and provides a detailed analysis of the drivers, restraints and opportunities in this market. It also surveys the competitive environment, including coverage of the pipeline activities adopted by market players, and it includes market projections for 2029. Also included are company profiles of key players, featuring detailed information regarding each company's business segments, financials, product portfolios and recent developments.

Report Includes:

- 15 data tables and 42 additional tables
- An analysis of the current and future global markets for gene editing therapeutics
- Analyses of global market trends, with market revenue data (sales figures) for 2021-2023, estimates for 2024, and projected CAGRs through 2029
- Estimates of the market size and revenue forecasts for the global gene editing therapeutics market, with market share analysis by region
- Discussion of the market dynamics, opportunities, and challenges, as well as emerging technologies
- Overview of sustainability trends and ESG developments in the industry, with emphasis on the ESG practices of leading companies, their ESG rankings, and consumer attitudes
- Competitive intelligence, including companies' market shares, recent M&A activity, and venture funding
- Company profiles of major players within the industry, including CRISPR Therapeutics, Vertex Pharmaceuticals, and Intellia Therapeutics

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Executive Summary

Summary:

Gene editing is a technique that precisely alters the genome sequence to introduce insertions, deletions or base substitutions. This technology holds promise for controlling diseases at the genetic level, particularly those genetic disorders caused by mutations in a single gene, as many diseases are associated with changes in gene expression in vivo. The evolution of gene editing technology can be categorized into three main generations: the first generation involves zinc-finger nucleases (ZFNs), the second generation utilizes transcription activator-like effector nucleases (TALENs), and the third and most widely used generation is the CRISPR/Cas9 system. Unlike ZFNs and TALENs, which target DNA strands using proteins, CRISPR technology guides Cas proteins to specific genome locations by altering the base sequence of a guide RNA segment, thereby enhancing gene editing efficiency and broadening the technology's applicability.

Gene editing therapeutics gained prominence over the last decade. The first therapeutic, Casgevy (exagamglogene autotemcel [exa-cel]), developed jointly by CRISPR Therapeutics and Vertex Pharmaceuticals, was approved in the U.K. in November 2023 and in the U.S. in December 2023. The approval of the first CRISPR/Cas9-based gene editing therapy is a game changer in this field. Casgevy is approved for genetic diseases, including sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT).

The gene editing therapeutics market consists of numerous small biotech firms that have been conducting research in this field. Approval of the first therapy has provided momentum to many of these companies. Numerous clinical trials are being conducted by various clinical stage biotech firms, but the majority of these trials are in the early stage of development. Approval of these therapies during the forecast period is therefore unlikely. The only product from Intellia Therapeutics, NTLA-2001, used for the treatment of transthyretin amyloidosis with cardiomyopathy (ATTR-CM), is in Phase III stage of development. The trial MAGNITUDE (NCT06128629) has its primary completion date listed as December 2027 and its estimated completion date as April 2028. If the ongoing pivotal trial has a positive outcome, the product will likely enter the market in late 2029 or sometime in 2030.

Table of Contents:

Table of Contents

Chapter 1 Executive Summary

Market Outlook

Scope of Report

Market Summary

Chapter 2 Market Overview

Introduction

Genome-Editing Tool Types

Meganucleases

Zinc Finger Nucleases

Transcription Activator-like Effector Nucleases

Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-Associated Protein 9

Gene editing Therapeutics

Chapter 3 Market Dynamics

Market Dynamics Snapshot

Market Drivers

Increasing Prevalence of Chronic Disease

Increasing Prevalence of Rare Genetic Disorders

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Precision Medicine
Increasing Strategic Initiatives
Market Restraints
Stringent Regulatory Frameworks and Time-Consuming Approval Processes
High Cost of Treatment
Adverse Events and Long-Term Monitoring
Lack of Skilled Workforce
Off-Target Impact
Market Challenges
Patent Disputes
Governmental Policies and Regulations
Ethical Issues
Market Opportunities
Chapter 4 Emerging Technologies and Developments
Introduction
Base Editing
Prime Editing
Cas-Clover and Cas-FOKI
CRISPR Interference and CRISPR Activation
RNA Editing
Artificial Intelligence in Genome Editing
Chapter 5 Pipeline Analysis
Overview
Clinical Trial Analysis Based on Technology
Clinical Trial Analysis Based on Diseases
Designations for Pipeline Drugs
Chapter 6 Patent Analysis
Chapter 7 Market Analysis
Introduction
Casgevy
Market Overview
Market Analysis
Market by Region
North America
Europe
Emerging Markets
Chapter 8 Competitive Intelligence
Strategic Initiatives
Competitive Landscape
Chapter 9 Sustainability in the Gene Editing Therapeutics Market: Environmental, Social and Governance (ESG) Perspectives
Introduction
ESG Practices in the Gene Editing Companies
Concluding Remarks from BCC Research
Chapter 10 Appendix
Methodology
Sources
Acronyms

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Company Profiles

ALLOGENE THERAPEUTICS

BEAM THERAPEUTICS

CARIBOU BIOSCIENCES INC.

CRISPR THERAPEUTICS

EDITAS MEDICINE

INTELLIA THERAPEUTICS INC.

PRECISION BIOSCIENCES

SANGAMO THERAPEUTICS

VERTEX PHARMACEUTICALS INC.

VERVE THERAPEUTICS INC.

VOR BIO

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Gene Editing Therapeutics Market

Market Research Report | 2024-08-30 | 111 pages | BCC Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$5500.00
	2-5 Users License	\$6600.00
	Site License	\$7920.00
	Enterprise License	\$9504.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-04"/>
		Signature	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

